{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:49:34Z","timestamp":1782906574267,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05510-3","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:01:50Z","timestamp":1704279710000},"page":"549-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An overlapping case of IgG4-related disease and systemic lupus erythematosus treated with belimumab: a case-based review"],"prefix":"10.1007","volume":"44","author":[{"given":"Megumi","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Asashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumina","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihei","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Toko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-9294","authenticated-orcid":false,"given":"Isao","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"5510_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539\u2013551. https:\/\/doi.org\/10.1056\/NEJMra1104650","journal-title":"N Engl J Med"},{"key":"5510_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH (2015) IgG4-related disease. Lancet 385:1460\u20131471. https:\/\/doi.org\/10.1016\/S0140-6736(14)60720-0","journal-title":"Lancet"},{"key":"5510_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, Okazaki K, Kawa S et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31:529\u2013533. https:\/\/doi.org\/10.1080\/14397595.2020.1859710","journal-title":"Mod Rheumatol"},{"key":"5510_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/82_2016_36","volume":"401","author":"T Kamisawa","year":"2017","unstructured":"Kamisawa T, Okazaki K (2017) Diagnosis and treatment of IgG4-related disease. Curr Top Microbiol Immunol 401:19\u201333. https:\/\/doi.org\/10.1007\/82_2016_36","journal-title":"Curr Top Microbiol Immunol"},{"key":"5510_CR5","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK et al (2016) Systemic lupus erythematosus. Nat Rev Dis Prim 2:16039. https:\/\/doi.org\/10.1038\/nrdp.2016.39","journal-title":"Nat Rev Dis Prim"},{"key":"5510_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"5510_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149095","volume":"131","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso Y, Toz B, Diamond B (2021) Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Investig 131:e149095. https:\/\/doi.org\/10.1172\/JCI149095","journal-title":"J Clin Investig"},{"key":"5510_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fmed.2020.00316","volume":"7","author":"I Parodis","year":"2020","unstructured":"Parodis I, Stockfelt M, Sj\u00f6wall C (2020) B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med 7:316. https:\/\/doi.org\/10.3389\/fmed.2020.00316","journal-title":"Front Med"},{"key":"5510_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"5510_CR10","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"5510_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2023.03.015","volume":"111","author":"V Batani","year":"2023","unstructured":"Batani V, Lanzillotta M, Mahajne J et al (2023) Association of IgG4-related disease and systemic rheumatic disorders. Eur J Intern Med 111:63\u201368. https:\/\/doi.org\/10.1016\/j.ejim.2023.03.015","journal-title":"Eur J Intern Med"},{"key":"5510_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71:1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"5510_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013545","volume":"97","author":"H Arai","year":"2018","unstructured":"Arai H, Hayashi H, Ogata S et al (2018) Progression of immunoglobulin G4-related disease to systematic lupus erythematosus after gastric cancer surgery: a case report. Medicine (Baltimore) 97:e13545. https:\/\/doi.org\/10.1097\/MD.0000000000013545","journal-title":"Medicine (Baltimore)"},{"key":"5510_CR14","doi-asserted-by":"publisher","first-page":"232470961986229","DOI":"10.1177\/2324709619862297","volume":"7","author":"S Naramala","year":"2019","unstructured":"Naramala S, Biswas S, Adapa S et al (2019) An overlapping case of IgG4-related disease and systemic lupus erythematosus. J Investig Med High Impact Case Rep 7:2324709619862297. https:\/\/doi.org\/10.1177\/2324709619862297","journal-title":"J Investig Med High Impact Case Rep"},{"key":"5510_CR15","volume":"15","author":"I Karageorgiou","year":"2023","unstructured":"Karageorgiou I, Pokharel A, Acharya I et al (2023) Overlapping tubulointerstitial lupus nephritis and immunoglobulin G4-related disease: a case report. Cureus 15:e40664","journal-title":"Cureus"},{"key":"5510_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0961203306073137","volume":"16","author":"S Kobayashi","year":"2007","unstructured":"Kobayashi S, Yoshida M, Kitahara T et al (2007) Autoimmune pancreatitis as the initial presentation of systemic lupus erythematosus. Lupus 16:133\u2013136. https:\/\/doi.org\/10.1177\/0961203306073137","journal-title":"Lupus"},{"key":"5510_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4103\/injr.injr_265_21","volume":"17","author":"S Padiyar","year":"2022","unstructured":"Padiyar S, Manwatkar A, Ganapati A et al (2022) Overlap of IgG4-Related disease with autoimmune rheumatic diseases: report of 2 cases and review of literature. Indian J Rheumatol 17:427\u2013431. https:\/\/doi.org\/10.4103\/injr.injr_265_21","journal-title":"Indian J Rheumatol"},{"key":"5510_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/mrcr\/rxac002","volume":"6","author":"Y Fujita","year":"2022","unstructured":"Fujita Y, Iwata S, Nakano K et al (2022) A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. Mod Rheumatol Case Rep 6:178\u2013182. https:\/\/doi.org\/10.1093\/mrcr\/rxac002","journal-title":"Mod Rheumatol Case Rep"},{"key":"5510_CR19","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1093\/rheumatology\/keac284","volume":"61","author":"Y Katayama","year":"2022","unstructured":"Katayama Y, Katsuyama T, Shidahara K et al (2022) A case of recurrent IgG4-related disease successfully treated with belimumab after remission of systemic lupus erythematosus. Rheumatology (Oxford) 61:e308\u2013e310. https:\/\/doi.org\/10.1093\/rheumatology\/keac284","journal-title":"Rheumatology (Oxford)"},{"key":"5510_CR20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/0961203319840430","volume":"28","author":"M Yamamoto","year":"2019","unstructured":"Yamamoto M, Aochi S, Suzuki C et al (2019) A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. Lupus 28:786\u2013789. https:\/\/doi.org\/10.1177\/0961203319840430","journal-title":"Lupus"},{"key":"5510_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12890-021-01781-3","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Liu Y, Shen X et al (2021) Clinicopathological characteristics of IgG4-related lung disease. BMC Pulm Med 21:413. https:\/\/doi.org\/10.1186\/s12890-021-01781-3","journal-title":"BMC Pulm Med"},{"key":"5510_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12931-020-01542-6","volume":"21","author":"J Kang","year":"2020","unstructured":"Kang J, Park S, Chae EJ et al (2020) Long-term clinical course and outcomes of immunoglobulin G4-related lung disease. Respir Res 21:273. https:\/\/doi.org\/10.1186\/s12931-020-01542-6","journal-title":"Respir Res"},{"key":"5510_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12890-016-0181-9","volume":"16","author":"X Sun","year":"2016","unstructured":"Sun X, Liu H, Feng R et al (2016) Biopsy-proven IgG4-related lung disease. BMC Pulm Med 16:20. https:\/\/doi.org\/10.1186\/s12890-016-0181-9","journal-title":"BMC Pulm Med"},{"key":"5510_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-239976","volume":"14","author":"NL Simon","year":"2021","unstructured":"Simon NL, Negmeldin M (2021) IgG4-related disease: a great mimicker of lung cancer. BMJ Case Rep 14:e239976. https:\/\/doi.org\/10.1136\/bcr-2020-239976","journal-title":"BMJ Case Rep"},{"key":"5510_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/ejcts\/ezx265","volume":"52","author":"A Zehnder","year":"2017","unstructured":"Zehnder A, Kocher GJ, Seitz M, Schmid RA (2017) IgG4-related disease of the lung: a rare differential diagnosis to lung cancer after positive positron emission tomography and biopsy. Eur J Cardiothorac Surg 52:1003\u20131004. https:\/\/doi.org\/10.1093\/ejcts\/ezx265","journal-title":"Eur J Cardiothorac Surg"},{"key":"5510_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1440-1827.2010.02524.x","volume":"60","author":"Y Sato","year":"2010","unstructured":"Sato Y, Notohara K, Kojima M et al (2010) IgG4-related disease: historical overview and pathology of hematological disorders. Pathol Int 60:247\u2013258. https:\/\/doi.org\/10.1111\/j.1440-1827.2010.02524.x","journal-title":"Pathol Int"},{"key":"5510_CR27","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/PAS.0b013e318157c068","volume":"32","author":"W Cheuk","year":"2008","unstructured":"Cheuk W, Yuen HKL, Chu SYY et al (2008) Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 32:671\u2013681. https:\/\/doi.org\/10.1097\/PAS.0b013e318157c068","journal-title":"Am J Surg Pathol"},{"key":"5510_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/modpathol.2009.17","volume":"22","author":"Y Sato","year":"2009","unstructured":"Sato Y, Kojima M, Takata K et al (2009) Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman\u2019s disease. Mod Pathol 22:589\u2013599. https:\/\/doi.org\/10.1038\/modpathol.2009.17","journal-title":"Mod Pathol"},{"key":"5510_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/572539","volume":"2012","author":"Y Sato","year":"2012","unstructured":"Sato Y, Yoshino T (2012) IgG4-related lymphadenopathy. Int J Rheumatol 2012:572539. https:\/\/doi.org\/10.1155\/2012\/572539","journal-title":"Int J Rheumatol"},{"key":"5510_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"5510_CR31","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2665-9913(23)00091-7","volume":"5","author":"M Rodziewicz","year":"2023","unstructured":"Rodziewicz M, Dyball S, Lunt M et al (2023) Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study. Lancet Rheumatol 5:e284\u2013e292. https:\/\/doi.org\/10.1016\/S2665-9913(23)00091-7","journal-title":"Lancet Rheumatol"},{"key":"5510_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/mr\/roac097","volume":"33","author":"H Yoshifuji","year":"2023","unstructured":"Yoshifuji H, Umehara H (2023) Glucocorticoids in the treatment of IgG4-related disease-prospects for new international treatment guidelines. Mod Rheumatol 33:252\u2013257. https:\/\/doi.org\/10.1093\/mr\/roac097","journal-title":"Mod Rheumatol"},{"key":"5510_CR33","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67:1688\u20131699. https:\/\/doi.org\/10.1002\/art.39132","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"5510_CR34","first-page":"186","volume":"36","author":"T Sasaki","year":"2018","unstructured":"Sasaki T, Akiyama M, Kaneko Y et al (2018) Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. Clin Exp Rheumatol 36(Suppl 1):186\u2013189","journal-title":"Clin Exp Rheumatol"},{"key":"5510_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/rheumatology\/keu228","volume":"54","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Nojima M, Takahashi H et al (2015) Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford) 54:45\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/keu228","journal-title":"Rheumatology (Oxford)"},{"key":"5510_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","volume":"74","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Mattoo H, Carruthers M et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74:190\u2013195. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205233","journal-title":"Ann Rheum Dis"},{"key":"5510_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14397595.2019.1650694","volume":"30","author":"H Tsuboi","year":"2020","unstructured":"Tsuboi H, Honda F, Takahashi H et al (2020) Pathogenesis of IgG4-related disease. Comparison with Sj\u00f6gren\u2019s syndrome. Mod Rheumatol 30:7\u201316. https:\/\/doi.org\/10.1080\/14397595.2019.1650694","journal-title":"Mod Rheumatol"},{"key":"5510_CR38","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar3810","volume":"14","author":"K Kiyama","year":"2012","unstructured":"Kiyama K, Kawabata D, Hosono Y et al (2012) Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther 14:R86. https:\/\/doi.org\/10.1186\/ar3810","journal-title":"Arthritis Res Ther"},{"key":"5510_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/14397595.2014.950036","volume":"25","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Yajima H, Takahashi H et al (2015) Everyday clinical practice in IgG4-related dacryoadenitis and\/or sialadenitis: results from the SMART database. Mod Rheumatol 25:199\u2013204. https:\/\/doi.org\/10.3109\/14397595.2014.950036","journal-title":"Mod Rheumatol"},{"key":"5510_CR40","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343\u20131349. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200937","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05510-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05510-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05510-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T18:03:14Z","timestamp":1707933794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05510-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["5510"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05510-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they do not have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient presented in this report gave written informed consent prior to submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}